Bayer, the pharmaceutical multinational, has inaugurated a new production facility at its headquarters in Berlin, after investing 130 million euros in the project.
This expansion is part of a multi-billion dollar investment program aimed at strengthening Bayer's global pharmaceutical production network.
The new facility in Berlin features cutting-edge technology, automated processes, and innovative production.
It is a key step in Bayer's global strategy to manufacture liquid pharmaceutical forms, such as injection and infusion solutions.
The company aims to supply the markets of the United States, Europe, and China with this investment.
Stefan Oelrich, member of the board of directors of Bayer AG and director of its pharmaceutical division, emphasizes the importance of following a clear innovation policy strategy oriented toward the future.
Kai Wegner, mayor of Berlin, underscores that this investment not only demonstrates loyalty to the location but also strengthens the city's position as a prominent health metropolis.
The new facilities are based on an innovative technology platform that covers a wide range of pharmaceutical parenteral products.
The highly digitalized manufacturing process enables the formulation, filling, and lyophilization of products in a safe, fast, and sterile manner. The facility focuses on critical areas with high medical demand, such as ophthalmological products.
With recorded profits of 4.150 billion euros in 2022, Bayer has quadrupled its earnings compared to the one billion euros in 2021, according to the latest published annual economic results.
This investment reflects Bayer's commitment to innovation, efficient production, and expansion of its presence in key markets.
With information from: PlantaDoce.
Receive all industry news in our weekly Newsletter Scientific Dialectics.